( December 16, 2025, 11:12 AM EST) -- WASHINGTON, D.C. — The U.S. Judicial Panel on Multidistrict Litigation on Dec. 15 agreed to centralize cases alleging that the use of glucagon-like peptide-I receptor agonist XE "glucagon-like peptide-I receptor agonist" (GLP-1 RA) medications caused permanent vision loss in the U.S. District Court for the Eastern District of Pennsylvania but found that the cases should be separated from cases in an MDL alleging gastrointestinal injuries....